Public market insider buying at SQI Diagnostics (SQD)

Public market insider buying at SQI Diagnostics (V:SQD)

Andrew Charles Morris, a Director, acquired 1,500,000 Common Shares on a direct ownership basis at a price of $0.440 on February 10th, 2021. This represents a $660,000 investment into the company's shares and an account share holdings change of 80.0%.

SQI Diagnostics is in the Advanced Medical Equipment & Technology Sub Industry Group under the Healthcare Sector.

SQI Diagnostics Inc (SQI) is a Canada-based diagnostics company. The Company develops multiplexed tests and automated systems for customers needing to measure a range of biomarkers in blood or other common sample types. It offers three different platforms sqidlite, sqid x and the siqdworks to run and analyze its microarray plates. Its Ig_plex microarrays have the ability to discriminate between individual isotypes of antibodies and antigens and proteins within a single well of a microarray. Its Ig_plex CHEX technology provides multiple in-microarray checks. It has three areas of focus: Testing for the drug development industry, Animal health testing, Human disease testing or deoxyribonucleic acid (DNA) diagnostic testing. In drug development testing, SQI provides technology and equipment for blood testing in clinical trials and pre-clinical research for developing various drugs. It applies its multiplexing technology to diagnostic tests used for customers in the animal health segment. SQI Diagnostics Inc. (SQD) has a high amount of executive buying compared to its small-cap peers in the market over the past three months. According to recent regulatory filings, one insider has invested a total amount of $660,000.